Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy

Shin Ichi Fujioka; Hiroyuki Shimomura; Kozo Fujio; Fusao Ikeda; Masanobu Miyake; Yasushi Ishii; Mamoru Itoh; Kosaku Sakaguchi; Takao Tsuji

Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy

Shin Ichi Fujioka, Hiroyuki Shimomura, Kozo Fujio, Fusao Ikeda, Masanobu Miyake, Yasushi Ishii, Mamoru Itoh, Kosaku Sakaguchi, Takao Tsuji

Graduate School of Medicine Dentistry and Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a ²²³Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.

Original language	English
Pages (from-to)	97-104
Number of pages	8
Journal	Hepatology Research
Volume	13
Issue number	2
Publication status	Published - Jan 1 1999

Keywords

Antiviral therapy
Hepatitis B virus
Hronic hepatitis
Lamivudine
Mutation

ASJC Scopus subject areas

Hepatology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{56c4055325274c5b8d69c9fb2e214332,

title = "Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy",

abstract = "Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a 223Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.",

keywords = "Antiviral therapy, Hepatitis B virus, Hronic hepatitis, Lamivudine, Mutation",

author = "Fujioka, {Shin Ichi} and Hiroyuki Shimomura and Kozo Fujio and Fusao Ikeda and Masanobu Miyake and Yasushi Ishii and Mamoru Itoh and Kosaku Sakaguchi and Takao Tsuji",

year = "1999",

month = jan,

day = "1",

language = "English",

volume = "13",

pages = "97--104",

journal = "Hepatology Research",

issn = "0928-4346",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy

AU - Fujioka, Shin Ichi

AU - Shimomura, Hiroyuki

AU - Fujio, Kozo

AU - Ikeda, Fusao

AU - Miyake, Masanobu

AU - Ishii, Yasushi

AU - Itoh, Mamoru

AU - Sakaguchi, Kosaku

AU - Tsuji, Takao

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a 223Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.

AB - Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a 223Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.

KW - Antiviral therapy

KW - Hepatitis B virus

KW - Hronic hepatitis

KW - Lamivudine

KW - Mutation

UR - http://www.scopus.com/inward/record.url?scp=0032938009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032938009&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032938009

SN - 0928-4346

VL - 13

SP - 97

EP - 104

JO - Hepatology Research

JF - Hepatology Research

IS - 2

ER -

Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this